Universe Pharmaceuticals UPC

NASDAQ UPC
$3.50 -0.40 (-10.26%)
As of: Oct 20, 2026 · 9:51 AM EDT

Universe Pharmaceuticals (UPC) stock price is $3.50, down 10.26% on the day, as of Oct 20, 2026. It has a market cap of $48.72Mn, and is classified in the Pharmaceuticals industry (Healthcare sector).

Key Stats
Market Cap48.72 Mn
Div. Yield0.00
Total Debt (Qtr)9.55 Mn
Add ratio to table…

About

Universe Pharmaceuticals INC is an offshore holding company incorporated in the Cayman Islands. Through its PRC operating entities the company manufactures markets sells and distributes traditional Chinese medicine products targeting the elderly population in China. The core activities include production of thirteen approved TCMD formulas and distribution of third party pharmaceutical medical devices and dietary supplements. The company generates revenue primarily from the…

Read more ↓
Sector: Healthcare Sector rationale The company's primary revenue comes from manufacturing and selling traditional Chinese medicine (TCMD) products, including chronic condition treatments and cold and flu medicines. It also distributes biomedical drugs and medical instruments to hospitals, clinics, and pharmaceutical distributors, all of which fall under the Healthcare sector. Industries: Pharmaceuticals Pharmaceuticals Primary The company manufactures and markets its own branded traditional Chinese medicine (TCMD) products, such as Bai Nian Dan and Hu Zhuo Ren, targeting chronic conditions and cold/flu. Revenue is primarily generated from the sale of these proprietary branded pharmaceutical formulas. Drug Distribution Drug Distribution Secondary The company earns additional income by distributing biomedical drugs, medical instruments, and dietary supplements manufactured by third-party producers to hospitals, clinics, and drugstore chains. Classified using BQ-MICS CIK: 0001809616

Product and Service Breakdown of Revenue (2025)

History
Peer group

Peer Comparison

Companies in the Pharmaceuticals
View all peers
S.No. Ticker Company Market CapP/EP/STotal Debt (Qtr)
1 LLY ELI LILLY & Co 1,153.65 Bn43.1914.4854.91 Bn
2 JNJ Johnson & Johnson 624.06 Bn29.666.3749.04 Bn
3 ABBV AbbVie Inc. 511.45 Bn81.057.9470.82 Bn
4 MRK Merck & Co., Inc. 365.76 Bn115.275.4953.91 Bn
5 NVS Novartis Ag 297.05 Bn18.835.429.59 Bn
6 AZN Astrazeneca Plc 260.90 Bn24.984.4532.35 Bn
7 AMGN Amgen Inc 234.34 Bn26.806.1557.30 Bn
8 UPC Universe Pharmaceuticals INC 0.05 Bn--0.01 Bn